Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

The Company that’s taking Psychedelics from ‘Underground to Mainstream’

(Click image to play video) On a trip to Amsterdam, an item on many traveler’s agendas would be to indulge in some famed Dutch truffles. It is an experience to heighten the mind that Canadian public Company Red Light Holland Corp. (TRIP) ( CSE: T...
Dave Jackson | February 2, 2021 |

Coverage Initiated on Maker of Antibiotic-Free Supplement for Livestock Feed

The highlights of this investment story are outlined in a Zacks Small-Cap Research report. In a Nov. 19 research note, analyst David Bautz reported that Zacks Small-Cap Research initiated coverage on Avivagen Inc. (VIV:TSX.V; CHEXF:OTCMKTS) with a US$2.50 valuation....
Streetwise Reports | November 27, 2019 |

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. This morning before U.S. markets opened, clinical-stage biopharmaceutical company Axsom...
Streetwise Reports | December 4, 2019 |

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection....
Streetwise Reports | October 4, 2019 |

China Social Media Firm Gains 55 Million Monthly Active Users

Weibo Corp. (WB:NASDAQ) , a leading Chinese social media platform company with nearly 500 million monthly active users, today announced its unaudited financial results for the second quarter ended June 30, 2019. In the report, the firm reported total n...
Streetwise Reports | August 20, 2019 |

How Investors Can Jump on the ESG Train

Back in August , we introduced our Stockhouse investor audience to a very different, and very profitable, kind of ESG company that’s been a market leader in Environmental Services – Vertex Resource Group Ltd. ( TSX-V.VTX , Forum ). In this exclusive ...
Dave Jackson | November 4, 2021 |

Is Uncle Sam about to inflate these stocks?

The easiest way to make money in the market is to find a stock the big investors are about to load up on and buy it first. You take your position early and enjoy the ride as big-money investors drive up the price… Well, speaking of big money… Nobody has deeper pocket...
David Eller | February 19, 2013 |

Surface Oncology Shares Trade Up 40% on Phase1 Study Plans for SRF617 Combined with Merck's KEYTRUDA

Shares of Surface Oncology set a new 52-week high price after the company reported that it is partnering with Merck & Co. in an immuno-oncology study of SRF617, targeting CD39 in combination with KEYTRUDA® (pembrolizumab) in solid tumor patients. Clinical-...
Streetwise Reports | May 21, 2020 |

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia

Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/...
Streetwise Reports | November 5, 2019 |

Sales of Antibiotic Alternative for Livestock Feed Accelerate in Asia

With antibiotic resistance a major health issue, the search is on for effective alternatives to replace antibiotics in livestock feed to promote growth. A small-cap Canadian company, Avivagen Inc. (VIV:TSX.V) , has developed a feed supplement, OxC-beta™ Livestock, wh...
Streetwise Reports | November 18, 2019 |
1 2 3 4 5 6 7 8 9 10 ...